Tumor vaccines in 2010: need for integration.
Induction of tumor-specific immunity is an attractive approach to cancer therapy, however to date every major pivotal trial has resulted in failure. While the phenomena of tumor-mediated immune suppression has been known for decades, only recently have specific molecular pathways been elucidated, and for the first time, rationale means of intervening and observing results of intervention have been developed. In this review we describe major advances in our understanding of tumor escape from immunological pressure and provide some possible therapeutic scenarios for enhancement of efficacy in future cancer vaccine trials.
Koos
David
D
Entest BioMedical, San Diego, CA, USA.
Josephs
Steven F
SF
Alexandrescu
Doru T
DT
Chan
Ray Chun-Fai
RC
Ramos
Famela
F
Bogin
Vladimir
V
Gammill
Vincent
V
Dasanu
Constantin A
CA
De Necochea-Campion
Rosalia
R
Riordan
Neil H
NH
Carrier
Ewa
E
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D018384:Oxidative Stress; D013601:T-Lymphocytes / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines